Related Experiment Video
Updated: Aug 15, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Alectinib-induced hemolytic anemia
Chung-Shien Lee1,2, Kevin Sullivan2
1College of Pharmacy and Health Sciences, Department of Clinical Health Professions, St John's University, Queens, NY, USA.
Introduction:
Alectinib is an oral anaplastic lymphoma kinase tyrosine kinase inhibitor with central nervous system activity. It is currently approved and a preferred first-line option for those with anaplastic lymphoma kinase-positive non-small cell lung cancer. Alectinib has been shown to cause anemia, usually mild.
Case Report:
We report a case of alectinib-induced hemolytic anemia in a patient receiving alectinib as first-line treatment for anaplastic lymphoma kinase-positive non-small cell lung cancer.
Management And Outcome:
The patient's dose was reduced from 600 mg twice daily to 450 mg twice daily and further down to 300 mg twice daily and eventually discontinued. At that point, the hemoglobin normalized.
Discussion:
Our case demonstrates objective evidence for hemolytic anemia induced by alectinib.
More Related Videos
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Physical Properties of Amines